This study thus proposes a novel regulatory axis involving METTL16, MROH8, and CAPN2, expanding our understanding of how m6A modifications influence pancreatic cancer progression and offering potential new therapeutic targets. This evidence concerns the gene METTL16 and familial pancreatic carcinoma.